Shanghai's CARsgen Opens CAR-T Manufacturing Facility

CARsgen Therapeutics opened its new manufacturing facility in Shanghai, which it will use to make its chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors. The facility will manufacture vectors and CAR-T cells to support CARsgen's clinical programs. CARsgen has two CAR-T trials underway, one for hepatocellular carcinoma and another for glioblastoma multiforme, plus it plans to file five IND applications to the CFDA and receive at least one IND approval from the US FDA by the end of 2018. More details.... Share this with colleagues: // //